Mobile

PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA)...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012786-58

PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA): A PHASE III, SINGLE ARM MULTICENTRE STUDY

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To model the PCA3 score change at 6 months post-treatment using a multivariate linear model and the following variables outcomes at baseline: age, Prostate Specific Antigen (PSA), clinical stage (TNM), pathological grade (Gleason score) and T2-ERG score.

Critère d'inclusion

  • Locally advanced or metastatic prostate cancer

Liens